© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 2, 120-127,
January 19, 2000
© 2000 Oxford University Press
Bcar1/p130Cas Protein and Primary Breast Cancer: Prognosis and Response to Tamoxifen Treatment
Affiliations of authors: S. van der Flier, A. Brinkman, E. M. Kok, L. C. J. Dorssers (Department of Pathology/Division of Molecular Biology), M. P. Look, M. E. Meijer-van Gelder, J. G. M. Klijn, J. A. Foekens (Department of Medical Oncology/Division of Endocrine Oncology), Josephine Nefkens Institute, University Hospital Rotterdam, The Netherlands.
Correspondence to: Lambert C. J. Dorssers, Ph.D., Department of Pathology/Division of Molecular Biology, Josephine Nefkens Institute, University Hospital Rotterdam, Rm. Be 432, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands (e-mail: dorssers{at}bidh.azr.nl).
BACKGROUND: The product of the Bcar1/p130Cas (breast cancer resistance/p130Crk-associated substrate) gene causes resistance to antiestrogen drugs in human breast cancer cells in vitro. To investigate its role in clinical breast cancer, we determined the levels of Bcar1/p130Cas protein in a large series of primary breast carcinomas. METHODS: We measured Bcar1/p130Cas protein in cytosol extracts from 937 primary breast carcinomas by western blot analysis. The levels of Bcar1/p130Cas protein were tested for associations and trends against clinicopathologic and patient characteristics, the lengths of relapse-free survival and overall survival (n = 775), and the efficacy of first-line treatment with tamoxifen for recurrent or metastatic disease (n = 268). RESULTS: Bcar1/p130Cas levels in primary tumors were associated with age/menopausal status and the levels of estrogen receptor and progesterone receptor. In univariate survival analysis, higher Bcar1/p130Cas levels were associated with poor relapse-free survival and overall survival (both two-sided P = .04; log-rank test for trend). In multivariate analysis, a high level of Bcar1/p130Cas was independently associated with poor relapse-free survival and overall survival. The response to tamoxifen therapy in patients with recurrent disease was reduced in patients with primary tumors that expressed high levels of Bcar1/p130Cas. In multivariate analysis for response, Bcar1/p130Cas was independent of classical predictive factors, such as estrogen receptor status, age/menopausal status, disease-free interval, and dominant site of relapse. CONCLUSION: Patients with primary breast tumors expressing a high level of Bcar1/p130Cas protein appear to experience more rapid disease recurrence and have a greater risk of (intrinsic) resistance to tamoxifen therapy. Thus, measurement of Bcar1/p130Cas may provide useful prognostic information for patients with primary or metastatic breast cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. van Agthoven, A. M. Sieuwerts, M. E. Meijer-van Gelder, M. P. Look, M. Smid, J. Veldscholte, S. Sleijfer, J. A. Foekens, and L. C.J. Dorssers Relevance of Breast Cancer Antiestrogen Resistance Genes in Human Breast Cancer Progression and Tamoxifen Resistance J. Clin. Oncol., February 1, 2009; 27(4): 542 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhao, C. Min, S. R. Vora, P. C. Trackman, G. E. Sonenshein, and K. H. Kirsch The Lysyl Oxidase Pro-peptide Attenuates Fibronectin-mediated Activation of Focal Adhesion Kinase and p130Cas in Breast Cancer Cells J. Biol. Chem., January 16, 2009; 284(3): 1385 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Q. Ta, K. S. Thomas, R. S. Schrecengost, and A. H. Bouton A Novel Association between p130Cas and Resistance to the Chemotherapeutic Drug Adriamycin in Human Breast Cancer Cells Cancer Res., November 1, 2008; 68(21): 8796 - 8804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Fox, T. M. Bernaciak, J. Wen, A. M. Weaver, M. A. Shupnik, and C. M. Silva Signal Transducer and Activator of Transcription 5b, c-Src, and Epidermal Growth Factor Receptor Signaling Play Integral Roles in Estrogen-Stimulated Proliferation of Estrogen Receptor-Positive Breast Cancer Cells Mol. Endocrinol., August 1, 2008; 22(8): 1781 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Singh, D. Dadke, E. Nicolas, I. G. Serebriiskii, S. Apostolou, A. Canutescu, B. L. Egleston, and E. A. Golemis A Novel Cas Family Member, HEPL, Regulates FAK and Cell Spreading Mol. Biol. Cell, April 1, 2008; 19(4): 1627 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Meijer, A. M Sieuwerts, M. P Look, T. van Agthoven, J. A Foekens, and L. C J Dorssers Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer Endocr. Relat. Cancer, March 1, 2008; 15(1): 101 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Schrecengost, R. B. Riggins, K. S. Thomas, M. S. Guerrero, and A. H. Bouton Breast Cancer Antiestrogen Resistance-3 Expression Regulates Breast Cancer Cell Migration through Promotion of p130Cas Membrane Localization and Membrane Ruffling Cancer Res., July 1, 2007; 67(13): 6174 - 6182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Riggins, K. S. Thomas, H. Q. Ta, J. Wen, R. J. Davis, N. R. Schuh, S. S. Donelan, K. A. Owen, M. A. Gibson, M. A. Shupnik, et al. Physical and Functional Interactions between Cas and c-Src Induce Tamoxifen Resistance of Breast Cancer Cells through Pathways Involving Epidermal Growth Factor Receptor and Signal Transducer and Activator of Transcription 5b. Cancer Res., July 15, 2006; 66(14): 7007 - 7015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Meijer, T. van Agthoven, P. T. Bosma, K. Nooter, and L. C.J. Dorssers Functional Screen for Genes Responsible for Tamoxifen Resistance in Human Breast Cancer Cells Mol. Cancer Res., June 1, 2006; 4(6): 379 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kostic and M. P. Sheetz Fibronectin Rigidity Response through Fyn and p130Cas Recruitment to the Leading Edge Mol. Biol. Cell, June 1, 2006; 17(6): 2684 - 2695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cabodi, A. Tinnirello, P. Di Stefano, B. Bisaro, E. Ambrosino, I. Castellano, A. Sapino, R. Arisio, F. Cavallo, G. Forni, et al. p130Cas as a New Regulator of Mammary Epithelial Cell Proliferation, Survival, and HER2-Neu Oncogene-Dependent Breast Tumorigenesis. Cancer Res., May 1, 2006; 66(9): 4672 - 4680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Becker, A. Sommer, J. R. Kratzschmar, H. Seidel, H.-D. Pohlenz, and I. Fichtner Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM Mol. Cancer Ther., January 1, 2005; 4(1): 151 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. J. Dorssers, N. Grebenchtchikov, A. Brinkman, M. P. Look, S. P. J. van Broekhoven, D. de Jong, H. A. Peters, H. Portengen, M. E. Meijer-van Gelder, J. G. M. Klijn, et al. The Prognostic Value of BCAR1 in Patients with Primary Breast Cancer Clin. Cancer Res., September 15, 2004; 10(18): 6194 - 6202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Grebenchtchikov, A. Brinkman, S. P.J. van Broekhoven, D. de Jong, A. Geurts-Moespot, P. N. Span, H. A. Peters, H. Portengen, J. A. Foekens, C.G.J. Sweep, et al. Development of an ELISA for Measurement of BCAR1 Protein in Human Breast Cancer Tissue Clin. Chem., August 1, 2004; 50(8): 1356 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C.J. Dorssers, N. Grebenchtchikov, A. Brinkman, M. P. Look, J. G.M. Klijn, A. Geurts-Moespot, P. N. Span, J. A. Foekens, and C.G.J. Sweep Application of a Newly Developed ELISA for BCAR1 Protein for Prediction of Clinical Benefit of Tamoxifen Therapy in Patients with Advanced Breast Cancer Clin. Chem., August 1, 2004; 50(8): 1445 - 1447. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cabodi, L. Moro, G. Baj, M. Smeriglio, P. Di Stefano, S. Gippone, N. Surico, L. Silengo, E. Turco, G. Tarone, et al. p130Cas interacts with estrogen receptor {alpha} and modulates non-genomic estrogen signaling in breast cancer cells J. Cell Sci., March 15, 2004; 117(8): 1603 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cai, A. Iyer, K. N. Felekkis, R. I. Near, Z. Luo, J. Chernoff, C. Albanese, R. G. Pestell, and A. Lerner AND-34/BCAR3, a GDP Exchange Factor Whose Overexpression Confers Antiestrogen Resistance, Activates Rac, PAK1, and the Cyclin D1 Promoter Cancer Res., October 15, 2003; 63(20): 6802 - 6808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Riggins, L. A. Quilliam, and A. H. Bouton Synergistic Promotion of c-Src Activation and Cell Migration by Cas and AND-34/BCAR3 J. Biol. Chem., July 18, 2003; 278(30): 28264 - 28273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Richer, B. M. Jacobsen, N. G. Manning, M. G. Abel, D. M. Wolf, and K. B. Horwitz Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells J. Biol. Chem., February 8, 2002; 277(7): 5209 - 5218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Fashena, M. B. Einarson, G. M. O'Neill, C. Patriotis, and E. A. Golemis Dissection of HEF1-dependent functions in motility and transcriptional regulation J. Cell Sci., January 1, 2002; 115(1): 99 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Ruest, N.-Y. Shin, T. R. Polte, X. Zhang, and S. K. Hanks Mechanisms of CAS Substrate Domain Tyrosine Phosphorylation by FAK and Src Mol. Cell. Biol., November 15, 2001; 21(22): 7641 - 7652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Schafer, E. S. Lee, R. M. O'Regan, K. Yao, and V. C. Jordan Rapid Development of Tamoxifen-stimulated Mutant p53 Breast Tumors (T47D) in Athymic Mice Clin. Cancer Res., November 1, 2000; 6(11): 4373 - 4380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Burnham, P. J. Bruce-Staskal, M. T. Harte, C. L. Weidow, A. Ma, S. A. Weed, and A. H. Bouton Regulation of c-SRC Activity and Function by the Adapter Protein CAS Mol. Cell. Biol., August 15, 2000; 20(16): 5865 - 5878. [Abstract] [Full Text]
|
|
|
|
|
|
S. F. Law, G. M. O'Neill, S. J. Fashena, M. B. Einarson, and E. A. Golemis The Docking Protein HEF1 Is an Apoptotic Mediator at Focal Adhesion Sites Mol. Cell. Biol., July 15, 2000; 20(14): 5184 - 5195. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. C. Jordan How Is Tamoxifen's Action Subverted? J Natl Cancer Inst, January 19, 2000; 92(2): 92 - 94. [Full Text] [PDF]
|
|
|
|
|
|
T. Gotoh, D. Cai, X. Tian, L. A. Feig, and A. Lerner p130Cas Regulates the Activity of AND-34, a Novel Ral, Rap1, and R-Ras Guanine Nucleotide Exchange Factor J. Biol. Chem., September 22, 2000; 275(39): 30118 - 30123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Stam, W. J. C. Geerts, H. H. Versteeg, A. J. Verkleij, and P. M. P. v. B. en Henegouwen The v-Crk Oncogene Enhances Cell Survival and Induces Activation of Protein Kinase B/Akt J. Biol. Chem., June 29, 2001; 276(27): 25176 - 25183. [Abstract] [Full Text] [PDF]
|
|